---
title: "U.S. stock market intraday update: Aptorum Group rises 118.17%"
description: "Aptorum rose 118.17%; Tharimmune rose 42.55%, with a transaction volume of USD 165 million; Protagenic Therapeutics rose 65.79%, with a transaction volume of USD 109 million; AbbVie rose 0.14%, with a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254013346.md"
published_at: "2025-08-21T13:32:52.000Z"
---

# U.S. stock market intraday update: Aptorum Group rises 118.17%

> Aptorum rose 118.17%; Tharimmune rose 42.55%, with a transaction volume of USD 165 million; Protagenic Therapeutics rose 65.79%, with a transaction volume of USD 109 million; AbbVie rose 0.14%, with a transaction volume of USD 39.7 million; Amgen fell 0.38%, with a market value of USD 159 billion

**U.S. Stock Market Midday Update**

Aptorum surged 118.17%, with increased trading volume. Based on recent important news:

1.  On August 21, DiamiR Biosciences and Aptorum announced the approval of CLEP testing by the New York State Department of Health, promoting innovative diagnostic testing, leading to a 118.17% increase in stock price.
    
2.  On August 19, the A-share market experienced a surge, driven by policies and industrial upgrades, with the machinery and electronics industry leading the gains.
    
3.  On August 20, the Hong Kong Stock Exchange announced its interim results, with shareholders' profit attributable rising 39% year-on-year, and market trading volume hitting a semi-annual high.
    

**Stocks with High Trading Volume in the Industry**

Tharimmune rose 42.55%, with increased trading volume. Based on recent important news:

1.  On August 20, Tharimmune released an initial beneficial ownership statement, listing Gary S. Stetz as the beneficial owner, which was positively received by the market, resulting in a significant 42.55% increase in stock price.
    
2.  On August 21, Tharimmune released another initial beneficial ownership statement, listing Vincent S. LoPriore as the beneficial owner, further driving up the stock price.
    
3.  On August 20, Tharimmune published news through ACCESS Newswire, boosting market confidence in the company's future development.
    

Protagenic Therapeutics rose 65.79%, with a trading volume of $109 million. Based on recent important news:

1.  On August 21, Protagenic Therapeutics announced a collaboration with Arrow to promote company development, leading to a significant 65.79% increase in stock price.
    
2.  On August 20, Stone Technology's semi-annual report showed a 67.28% increase in R&D investment, enhancing market confidence in the high-tech sector.
    
3.  On August 18, Soligenix received FDA orphan drug designation, with its stock price rising 47.5%, driving up related biotech stocks.
    

AbbVie rose 0.14%, with increased trading volume. Based on recent important news:

1.  On August 21, AbbVie announced positive results from its Phase 3 UP-AA study, showing significant effects of upadacitinib in treating patients with severe alopecia areata, driving up the stock price.
    
2.  On August 19, AbbVie completed its acquisition of Capstan Therapeutics, a deal valued at up to $2.1 billion, strengthening its position in the autoimmune disease field.
    
3.  On August 18, AbbVie's dividend yield was 3.2%, significantly higher than the average level of the S&P 500, attracting long-term investors **Stocks Ranked Among the Top by Market Capitalization in the Industry**
    

Amgen fell 0.38%, with increased trading volume. Based on recent key news:

1.  On August 20, MarketBeat pointed out that Amgen was not included in the list of five stocks recommended by top analysts, leading to a decline in investor confidence and a drop in stock price.
    
2.  On August 18, MarketBeat reiterated that Amgen was only rated as a hold, with better investment options available, further dampening market sentiment.
    
3.  On August 20, the news of Hansoh Pharmaceutical's share placement attracted market attention to pharmaceutical stocks, but Amgen failed to benefit and was instead negatively impacted

### Related Stocks

- [APM.US - Aptorum](https://longbridge.com/en/quote/APM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 恢復石油交易 美國準企業參與委內瑞拉油氣業 | 美國進一步放寬對委內瑞拉石油產業的限制，允許美企參與當地石油業務。財政部發布許可，支持與委內瑞拉政府及國營石油公司（PDVSA）的商業往來，提供探勘、開發、生產石油或天然氣所需的資源。能源部長萊特計劃前往委內瑞拉進行相關會談。 | [Link](https://longbridge.com/en/news/275566222.md) |
| 美眾議院投票否決對加拿大加徵關税 6 名共和黨議員倒戈 | 美國眾議院通過法案，試圖終止川普對加拿大的關税，顯示出白宮經濟政策的脆弱性。儘管 6 名共和黨議員倒戈，法案通過的可能性仍然微乎其微。川普威脅否決該法案，並考慮退出《美墨加貿易協定》，加劇北美貿易緊張。共和黨在保住眾議院和參議院控制權方面面 | [Link](https://longbridge.com/en/news/275693309.md) |
| SoFi 與 OSL 集團 (863) 達戰略合作，引入數字資產交易服務，業務首次擴張至美國本土以外市場 | SoFi Securities（香港）有限公司與 OSL 集團達成戰略合作，首次將數字資產交易服務擴展至美國以外市場。此合作為香港投資者提供通過 SoFi Hong Kong 應用程式交易多種數字資產的機會，標誌著 SoFi 全球業務的重要 | [Link](https://longbridge.com/en/news/275689746.md) |
| 周大福 (1929) 內地門店據報春節後調高金飾售價最多 30% | 周大福計劃於春節後調高金飾售價，漲幅預計在 15% 至 30% 之間。部分門店已接獲通知，具體調價細節待實際更換價格標籤確認。調價原因是受國際及國內市場因素影響，黃金及原材料價格持續上漲。集團要求各部門及門店提前做好價格管理工作，以確保調價 | [Link](https://longbridge.com/en/news/275546562.md) |
| 美國通脹再回落 市場料最快 6 月減息 道指早段挫逾 300 點後倒升 | 美國通脹回落，1 月 CPI 按年升 2.4%，低於預期，推動美股反彈。道指一度跌 367 點後回升，最終上漲 61 點。市場對 6 月減息的預期上升至 66%。專家認為，通脹放緩有利於美股牛市，預計今年將減息兩次，最早在 6 月。 | [Link](https://longbridge.com/en/news/275920384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.